The treatment of hypertension in the elderly has to take into account co-existing pathology. However, the benefit from treatment are large in terms owing to the frequency of cardiovascular events in the elderly. The benefits observed in randomised controlled trials are reviewed together with the adverse effects of the individual treatments. The optimal use of anti-hypertensive treatment is considered in light of any concomitant dis-
Introduction
For a long time hypertension in the elderly has been raising many queries with indefinite and uncertain answers. Does blood pressure (BP) lowering reduce the incidence of mortality and morbidity in elderly people as in younger people? What BP level should be treated pharmacologically? How far should it be lowered? What drug should we choose, considering that elderly people often suffer from many different conditions? Are the benefits associated with antihypertensive treatment more than the risks in older age? In the last few years trials have been published and many questions have been answered. However, some problems are still unresolved and need to be clarified, for example the treatment of hypertensive people over 80 years old. In fact two trials involving people over this age failed to show a benefit for treatment, 2, 5 but one trial suggests a benefit. 4 The problem may be due to the small number of subjects in the samples aged over 80.
The characteristics of the principal trials [1] [2] [3] [4] [5] [6] [7] in the elderly and their outcomes are shown in Tables 1  and 2 , respectively. Although these trials were not set up to study total mortality, treatment of hypertension tended to lower total deaths in all studies and statistical significance was reached in the STOPHypertension trial 5 with a reduction of 43%. The main benefits of anti-hypertensive therapy were seen in the large, significantly reduced incidence of total cardiovascular events in six trials, 2-7 ranging from 17 to 40%. This effect was mainly due to the significant fall, between 25 and 47%, in the combined non-fatal and fatal stroke events. All trials also showed a reduction in total cardiac events, but statistical significance was achieved only in the Systolic Since the benefits in these trials were seen by lowering BP below the entry levels it can be assumed that in patients with combined systolic and diastolic hypertension the pressure should be reduced below 160 and 90 mm Hg, respectively, and for ISH systolic pressure should be lowered below 160 mm Hg. The trial data do not support a J-shaped curve 3 implicating an increase in cardiac mortality at low levels of diastolic BP. In the SHEP trial 4 diastolic pressure fell in the actively treated group from 77 to 68 mm Hg with a 27% reduction in cardiac mortality.
The drugs administered as a first step treatment during the trials were either a potassium losing diuretic, 1,2,4-6 with 2,5,6 or without 1,4 a potassium sparing diuretic, or a beta-blocker (BB). 3, 5, 6 As a second step treatment a BB, 4-6 a central acting drug 2, 3 or a diuretic 5, 6 were added as shown in Table 1 . After analysing the results of six trials, five of which were based on diuretics as a first-line treatment, Beard et al 8 considered diuretics the drug of first choice in the management of hypertension in the elderly (Table 2 ). These authors did not consider a BB as first choice treatment in the hypertensive elderly since this drug failed to reduce mortality from cardiac events in the MRC study 6 (Table 3 ), although they produced a similar pressure reduction to diuretics, raising the hypothesis that diuretics might not only act by lowering BP. When added to a diuretic regime, such as in the SHEP trial 4 , BBs produced excellent results. When employed first, as in Coope and Warrender 3 and in the STOP trial 5 the incidence of stroke was reduced, but the reduction in total cardiac events were modest at −15% and −13%, respectively. Nevertheless, BBs remain the drug of choice in hypertensive patients with angina or a previous myocardial infarction. In a recently completed trial, the SYST-EUR 7 trial in ISH, first-line treatment was a calcium channel blocker (CCB), nitrendipine, with the possible addition of an angiotensin-converting enzyme (ACE) inhibitor, enalapril, and/or a diuretic, hydrochlorothiazide. The treatment produced a statistically significant reduction in all strokes (−42%) and all cardiac events (−26%). This study did not confirm an increase in myocardial infarction, 9,10 gastrointestinal bleeding 11 and cancer 12 recently reported in association with short acting CCB use. Apart from the SYST-EUR study where a CCB in elderly people has been shown to reduce cardiovascular mortality and morbidity in ISH, randomised trials evaluating the effects of newer drugs, known to be effective in reducing high BP, such as ACE-inhibitors, alphablockers and angiotensin II (AT2) receptor antagonists, have not yet been reported. The Hypertension in the Very Elderly Trial (HYVET, pilot) 13 is addressing the effect of a starting treatment with a diuretic or an ACE inhibitor with or without a CCB in combined systolic and diastolic hypertension in people aged over 80 years. Hopefully, this trial will fill the lack in our knowledge about the benefit to risk comparison from lowering BP in people at this age. Table 4 provides the benefit:risk comparison 14 for the EWPHE and MRC trials. For diuretics adverse effects include hypokalaemia, dyslipidaemia, increased serum urate and creatinine concentrations and impaired glucose tolerance. Thiazide-induced hypokalaemia may be avoided by using a potassium Tailoring anti-hypertensive treatment in the elderly S Bonapace et al 619 sparing diuretic and this is particularly important in those on digoxin. Adverse changes in glucose and lipid metabolism could be important in elderly people, but the benefits of BP lowering are greater. Beta-blockers may worsen the metabolic profile and they are also associated with lethargy, depression, sleeplessness, nightmares and cold extremities. It is clear that anti-hypertensive treatment can affect the biochemical profile or pre-existing diseases and also impair the quality of life of a patient. Modification of symptomatic well-being, psychological wellbeing, cognitive function and activities such as sleeping, working, social and sexual functioning, have been reported by many authors. 15, 16 Side effects such as bronchospasm due to BBs, constipation due to verapamil, cough due to ACE inhibitors, impotence due to BBs or ankle swelling secondary to nifedipine may affect the quality of life in younger or older patients. Therefore the choice of an antihypertensive treatment should be led by coexistent disease, by the side effects of the drugs, by the possible drug interactions and by changes in symptoms and quality of life. The newer drugs may be used particularly where diuretics and beta-blockers are contraindicated, always bearing in mind that their benefits in terms of morbidity and mortality in treating hypertension have not always been confirmed.
Tailoring of treatment to the individual patient
Fitting a treatment to an elderly person with high BP as the only disease will be easy and the choice will mainly fall on a diuretic. But in many of the elderly, tailoring the most suitable therapy is necessary because of the presence of concomitant diseases such as heat failure, ischaemic heart disease, chronic lung disease, peripheral vascular disease, prostatic hypertrophy, impotence, diabetes, gout, constipation and glaucoma (Table 5 ) and simultaneous use of many other drugs (Table 6 ). Morever, aging is associated with physiological haemodynamic changes such as a lower stroke volume and an impaired baroreceptor reflex that can determine different responses to drugs leading, for example, to an increased risk of orthostatic hypotension. To avoid adverse drug effects and allow the preservation of autoregulation and cerebral and cardiac perfusion it is advisable to start with a reduced dosage of drugs, especially in the elderly.
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Conclusion
The trial data have shown that hypertension should be treated in all patients aged 65 to 80 years and BP values should be lowered below 160 and 90 mm Hg, or probably lower 18 for systolic and diastolic, respectively. Lowering BP in the elderly has greater absolute benefits in terms of preventing stroke or coronary events compared with younger patients, as these are more frequent in the elderly. Diuretics are still the first choice drug in uncomplicated hypertension and the least expensive. Newer drugs should be employed in the presence of concomitant diseases and/or drug treatments.
